TY 2020 Form 990 Schedule M

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..	X		4,740,349	Cost
5 Clothing and household goods .......	X		112,948,706	Cost
6 Cars and other vehicles ..	X	2	89,900	Cost
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...	X	948	27,553,067	Cost
20 Drugs and medical supplies .	X	7,510	436,051,095	Cost - See Part II
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( Bldg Material )	X	344	10,902,768	Cost
26 Other ( Educational )	X	760	9,824,138	Cost
27 Other ( Miscellaneous )	X	557	5,302,671	Cost
28 Other ( Agriculture )	X	39	623,254	Cost

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

Yes

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

Return Reference	Explanation
Part I, Column (b):	The number of contributions represent the number of contributions received, not the number of items donated. Schedule M, Part I, Line 20: Beginning January 1, 2020, Pharmaceutical Gift-in-Kind (GIK) contributions received are valued using costing data acquired from recognized and published resources and are valued at their estimated National Average Drug Acquisition Cost ("NADAC") on a drug by drug basis. If NADAC is not available, such items are valued at their estimated wholesale acquisition cost ("WAC") also on a drug by drug basis. If WAC is not available in any published source, the Organization will refer to the donor's value. NADAC costs are transactional wholesale costs (wholesale value less discounts, incentives, etc.), whereas WAC values are manufacturers' published wholesale values (no discounts, incentives, etc.). This current valuation policy most resembles one used by a wholesale distributor of goods, which is the market role the Organization has in the acquisition and shipment of pharmaceutical donations. Pharmaceutical GIK contributions acquired from non-U.S. donors for products legally permissible to be sold outside the United States are valued in U.S. dollars based upon the wholesale market price of the countries representing the principal exit markets for those products.
Part I, Line 32b:	The Organization contracted a third party to receive and process a small portion of noncash contributions such as gold jewelry, passenger vehicles, and grain commodities. This service was discontinued during the 4th quarter of 2020.

Return Reference

Explanation

Part I, Column (b):

The number of contributions represent the number of contributions received, not the number of items donated. Schedule M, Part I, Line 20: Beginning January 1, 2020, Pharmaceutical Gift-in-Kind (GIK) contributions received are valued using costing data acquired from recognized and published resources and are valued at their estimated National Average Drug Acquisition Cost ("NADAC") on a drug by drug basis. If NADAC is not available, such items are valued at their estimated wholesale acquisition cost ("WAC") also on a drug by drug basis. If WAC is not available in any published source, the Organization will refer to the donor's value. NADAC costs are transactional wholesale costs (wholesale value less discounts, incentives, etc.), whereas WAC values are manufacturers' published wholesale values (no discounts, incentives, etc.). This current valuation policy most resembles one used by a wholesale distributor of goods, which is the market role the Organization has in the acquisition and shipment of pharmaceutical donations. Pharmaceutical GIK contributions acquired from non-U.S. donors for products legally permissible to be sold outside the United States are valued in U.S. dollars based upon the wholesale market price of the countries representing the principal exit markets for those products.

Part I, Line 32b:

The Organization contracted a third party to receive and process a small portion of noncash contributions such as gold jewelry, passenger vehicles, and grain commodities. This service was discontinued during the 4th quarter of 2020.

Software ID:
Software Version: